Inspire Medical Systems, Inc. INSP
64.33 USD +0.35 (+0.55%)
At closeNov 10, 2026, 7:23 AM EST
62.45 -1.88 -2.92%
Pre-market · Nov 10, 7:23 AM ET
62.93 Day range 64.74
38.91 52-week range 147.03
- YTD
- -30.25%
- 1 year
- -21.35%
- Market cap
- 1.86B
- Revenue (ttm)
- 880.94M
- Profit margin
- 11.43%
- EPS (ttm)
- 3.35
- Shares out
- 28.97M
- P/E ratio
- 19.20
- Forward P/E
- 43.00
- YTD return
- -30.25%
- 1-year return
- -21.35%
- Volume
- 521.59K
- Avg volume
- 758.79K
- Open
- 64.01
- Previous close
- 63.98
- Day's range
- 62.93 – 64.74
- 52-week range
- 38.91 – 147.03
- Beta
- 0.65
- Analysts
- Hold
- Price target
- 69.63 (+8.2%)
- Earnings date
- Feb 10, 2027
5D -4.58 (-6.65%)
Key statistics
- Enterprise value
- 1.55B
- PEG ratio
- 0.00
- Price / sales
- 2.12
- Price / book
- 2.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -7.90%
- Free cash flow
- 76.29M
- Total cash
- 327.97M
- Total debt
- 28.61M
- Return on equity
- 13.49%
- Short % of float
- 20.31%
- 50-day average
- 68.97
- 200-day average
- 57.90
Analyst view
Consensus: hold
Hold
Price target (mean) 69.63 +8.2% upside
Now 64.33
- Target (low)
- 45.00
- Target (mean)
- 69.63
- Target (high)
- 97.00
Ratings (0m) 18 4 buy · 11 hold · 3 sell
- Strong buy0
- Buy4
- Hold11
- Sell1
- Strong sell2
Next earnings
Feb 10, 2027
Expected Feb 10, 2027. Consensus EPS estimate 0.91623.
Financials — quick view
INSP Revenue — quarterly 206.69M
INSP Net income — quarterly -24.39M
INSP EPS — quarterly -0.84
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2027 | Dec 30, 2026 | 0.91 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | 0.08701 | 0.14 | +0.05 | +60.90% |
| Aug 3, 2026 | Jun 30, 2026 | -0.23592 | 0.14 | +0.38 | +159.34% |
| May 4, 2026 | Mar 31, 2026 | -0.27533 | 0.10 | +0.38 | +136.32% |
| Feb 11, 2026 | Dec 31, 2025 | 0.69 | 1.65 | +0.96 | +139.13% |
| Nov 3, 2025 | Sep 30, 2025 | -0.15 | 0.38 | +0.53 | +353.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | JP Morgan | main | Neutral | Neutral |
| Nov 3, 2026 | Truist Securities | reit | Hold | Hold |
| Nov 3, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Nov 3, 2026 | Evercore ISI Group | main | In-Line | In-Line |
| Nov 3, 2026 | Barclays | main | Underweight | Underweight |
| Nov 3, 2026 | Piper Sandler | main | Neutral | Neutral |
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- inspiresleep.com
News
Inspire Medical Systems: The Moat Just Passed Its Worst-Case Stress Test 
Inspire Medical Systems, Inc. to Present at the Stifel 2026 Healthcare Conference 
JP Morgan Maintains Neutral on Inspire Medical Systems, Raises Price Target to $65 
Truist Securities Reiterates Hold on Inspire Medical Systems, Lowers Price Target to $76 - Wells Fargo Maintains Equal-Weight on Inspire Medical Systems, Raises Price Target to $69
Evercore ISI Group Maintains In-Line on Inspire Medical Systems, Lowers Price Target to $60 
Barclays Maintains Underweight on Inspire Medical Systems, Lowers Price Target to $62 
These Analysts Increase Their Forecasts On Inspire Medical After Strong Q3 Results 
These Analysts Increase Their Forecasts On Inspire Medical After Strong Q3 Results - Piper Sandler Maintains Neutral on Inspire Medical Systems, Raises Price Target to $70
Your note
Sign in to keep a note on INSP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BUCHHOLZ RICHARD | Chief Financial Officer | Sale | Aug 28, 2025 | 50,767 |
| HERBERT TIMOTHY P | Chief Executive Officer | Stock Award(Grant) | Feb 19, 2026 | 163,492 |
| KELLY JASON P | Officer | Sale | Aug 6, 2026 | 18,985 |
| MANN MELISSA | Officer | Stock Award(Grant) | Feb 19, 2026 | 23,609 |
| MCCORMICK SHAWN T | Director | Sale | May 7, 2026 | 30,712 |
| MEAD DANA G JR | Director | Stock Award(Grant) | Apr 29, 2026 | 26,213 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.36% | 4,737,519 | 304.79M | Jun 29, 2026 |
| Wellington Management Group, LLP | 8.23% | 2,382,660 | 153.29M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 7.21% | 2,088,961 | 134.39M | Jun 29, 2026 |
| Soleus Capital Management, L.P. | 6.67% | 1,931,436 | 124.26M | Jun 29, 2026 |
| AQR Capital Management, LLC | 6.41% | 1,856,800 | 119.46M | Jun 29, 2026 |
| UBS Group AG | 5.68% | 1,645,511 | 105.86M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 7.23% | 2,093,826 | 134.71M | Jul 30, 2026 |
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.94% | 1,720,772 | 110.71M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 914,149 | 58.81M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.59% | 750,208 | 48.26M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 660,263 | 42.48M | Jun 29, 2026 |
| Artisan Partners Funds Inc.-Artisan International Small-Mid Fund | 1.57% | 456,014 | 29.34M | Jun 29, 2026 |